Join expert faculty as they take a deep dive into the latest clinical evidence and practical considerations for the personalized treatment of patients with myelofibrosis (MF) with JAK inhibitors and beyond. This recording from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA features a review of the novel mechanisms of action and disease-modifying potential of emerging MF therapies reinforced through interactive polling questions and a 2D animation video, as well as expert insights on the potential positioning of these agents into MF treatment plans. You will also have access to download an up-to-date Myelofibrosis Clinical Trial Pocket Guide to support the differentiation of the evolving landscape based on mechanisms of action, clinical trial design, and disease-modifying endpoints. Don’t miss this opportunity to prepare for the MF treatment paradigm shift, bringing combination therapy and disease modification to the forefront of patient-centered care and durable outcomes.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/unleashing-emerging-therapies-modify-myelofibrosis-pathogenesis-shifting
- Start Date: 2024-12-30 06:00:00
- End Date: 2024-12-30 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Geron - Amount: 29750.0 - Is Kind Support: False Source: Incyte Corporation - Amount: 22500.0 - Is Kind Support: False Source: Morphosys - Amount: 44750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology